Rx-360, a global nonprofit pharmaceutical supply chain consortium, announced on Tuesday that it has partnered with Leucine, an AI-powered pharmaceutical manufacturing and compliance platform.
Through this collaboration, Rx-360 consortium members will receive complimentary access to Leucine's FDA Tracker Premium, an advanced regulatory intelligence platform designed to help pharmaceutical manufacturers proactively monitor FDA activity, assess risk, and stay continuously inspection-ready.
FDA Tracker Premium delivers real-time intelligence across FDA inspections, Form 483s, and warning letters -- providing deep analytics on investigators, subsystems, and enforcement trends.
The platform helps quality and compliance leaders predict potential risks, benchmark performance against industry peers, and prepare more effectively for upcoming inspections, Rx-360 said.
Rx-360 partners with Leucine to offer access to regulatory intelligence platform
Lunai Bioworks receives first LOI to license next-generation immune cell therapy
Active Biotech to receive US patent for tasquinimod formulation
Sanofi and Regeneron's Dupixent approved in EU for chronic spontaneous urticaria
Clearmind Medicine advances global CMND-100 AUD trial with first patient enrolled in Israel
NeuroSense's PrimeC receives FDA clearance for pivotal Phase 3 trial in ALS
Made Scientific enters manufacturing partnership with Cellergy Therapeutics
Novartis' Itvisma granted US FDA approval for spinal muscular atrophy treatment
Avidity Biosciences announces US Managed Access Program for delpacibart zotadirsen (del-zota)
Nuvalent's zidesamtinib NDA filing accepted by US FDA
Mycovia Pharmaceuticals publishes long-term efficacy results from extension study of VIVJOA
BioNet receives positive opinion from EMA for VacPertagen marketing authorisation in EU
AbbVie receives approval for EPKINLY, rituximab and lenalidomide combination